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Abstract
The 2002 Keystone symposia held in Taos, New Mexico (21–26 February) saw the conver-
gence of two related ﬁelds; Epigenetics in Development and Disease, and RNA Interfer-
ence, Cosuppression and Related Phenomena. The meeting highlights presented here
concentrate upon the sessions within the Epigenetics in Development and Disease meeting,
although there were joint sessions which will also be discussed. Of course epigenetic
regulation is not restricted to the vertebrates but I have chosen, rightly or wrongly, to limit
the highlights to those concerning vertebrates. Copyright # 2002 John Wiley & Sons, Ltd.
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Sadly the principle organiser of the meeting, Alan
Wolffe, died in 2001. Internationally recognised for
his research on chromatin structure and its role in
the regulation of gene expression, Dr Wolffe was
paid many tributes from friends and colleagues
throughout the meeting.
As a newcomer to the ﬁeld of Epigenetics, having
spent nine years working in the mapping and sequ-
encing of the human genome and its four bases
Adenine (A), Cytosine (C), Guanine (G) and Thy-
mine (T) it was clear that I’d been missing the all
important 5
th base of DNA, namely 5-methylcytosine
(m
5C) and the epigenome. The importance of m
5C
in both development and disease would become
very clear in the days to come.
In his keynote address, Peter Jones (University of
Southern California) gave a summary of the epige-
netics of cancer (the fusion of ﬁelds, DNA methyla-
tion and chromatin structure) and a ﬂavour of talks
to come. Clusters of the unmethylated dinucleotide
CpGs (more commonly known as CpG islands) are
present in the promoter and exonic sequences of
approximately 40% of mammalian genes, whereas
other regions of mammalian genomes contain few
CpG dinucleotides, which are largely methylated.
m
5C is mutagenic (discussed later) which probably
explains the decreased occurrence of CpGs over
evolutionary time. Following a comprehensive analy-
sis of CpG islands in human chromosomes 21 and
22 [9] a new deﬁnition of CpG islands was pro-
posed, differing from that ﬁrst established by
Gardiner–Garden and Frommer in 1987 [4]. The
new deﬁnition includes a G+C content greater than
or equal to 55% (compared to 50%) and an obser-
ved CpG over expected CpG of 0.65 (compared to
0.6) in a sequence of 500 bp or more (compared to
200 bp). Importantly, this excludes most Alu repe-
titive sequences, which are generally methylated
and therefore suppressed. It is well established that
the methylation of promoter CpG islands plays
an important role in X chromosome inactivation,
genomic imprinting, silencing of intragenic parasites
and carcinogenesis.
In cancerous cells there is a general reduction of
approximately 10% of the 5-methylcytosines. How-
ever there is an increase in methylation at CpG
islands, including those of tumour suppressor genes
(TSGs) which results in their silencing. Normal
tissues also show an increase in methylation over
time (aging) at CpG islands and age is the greatest
risk factor in cancer. Encouragingly, hypomethylat-
ing drugs such as Zebularine may reverse the
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Copyright # 2002 John Wiley & Sons, Ltd.methylation status and therefore reactivate TSGs
silenced in cancers.
Knudson’s ‘two-hit’ hypothesis proposes that
mutation of one allele and loss of the other (loss
of heterozygosity) is responsible for cancer [5].
Jones concluded that one of the hits may involve
methylation.
DNA methylation and human disease
Stephen Baylin (The John Hopkins University)
chaired and opened this session with a discussion
of promoter hypermethylation and silencing of genes
in cancer. Every major form of cancer has a con-
tribution from promoter hypermethylation [3] but
what happens at promoters that leads to hyper-
methylation and perhaps tumours? To address this
question Baylin and colleagues studied E-cadherin
CpG islands in normal and cancerous cells. They
found that over time (aging) methylation bound-
aries are breached, resulting in inappropriate methy-
lation of CpG islands and suppressed transcription.
Suppression of TSGs gives rise to neoplasia. DNA
methyltransferases (DNMTs) interact with multiple
different factors including histone deacetylases
(HDACs). DNMTs target unmethylated CpG
islands and the subsequent methylation of these
CpG islands attracts the methyl binding protein
(MBP) machinery of the cell. Experiments using
inhibitors of DNMTs, such as 5-aza-cytidine, show
that methylation behaves as a lock for transcrip-
tional silencing. Histone deacetylase prevents trans-
cription and therefore there is a synergy between
acetylation and methylation.
In an attempt to identify novel TSGs a micro-
array containing 10 000 genes was used to study
gene expression in colon cancer. Approximately 250
genes were observed with altered expression and the
subset of these genes containing CpG islands were
all methylated in the tumours. To conﬁrm the TSG
role of one such gene (HIC1), knockout experi-
ments were performed on heterozygous HIC1 mice.
Methylation was not observed on the mutated allele
when this was the only allele inherited, consistent
with Knudson’s ‘two-hit’ hypothesis [5].
Brian Hendrich (Centre for Genome Research,
University of Edinburgh) discussed the role of
methyl-CpG binding proteins in development and
disease. Rett syndrome is a disturbing condition in
which, after a period of apparently normal devel-
opment, children lose the ability to speak and walk,
developingincessanthand-wringingmotions,seizures
and scoliosis. The syndrome is the result of muta-
tions in the ubiquitously expressed methyl-CpG
binding protein MeCP2. The MeCP2 gene resides on
the X chromosome and therefore, as a result of
mosaic inactivation, females carrying heterozygous
MeCP2 mutations deteriorate and then plateau,
whilst males null for MeCP2 die within two years.
Most missense mutations occur in two known func-
tional domains and a website containing all known
mutations in the MeCP2 gene can be found at:
http://homepages.ed.ac.uk/skirmis/. MeCP2 knock-
outs in mice have provided a model for the sub-
sequent study of Rett syndrome and show the
requirement for MeCP2 within the central nervous
system.
Gerd Pfeifer (City of Hope National Medical
Center) continued with the theme of methyl-CpG
binding domain proteins (MBDs) and in his short
talk introduced a new member of the MBD family,
MBD3L. MBD3L, a gene homologous to the
methyl-CpG binding domain protein genes MBD3
and MBD2, is expressed speciﬁcally in postmeiotic
cells of the testis. MBD3L has a coiled-coil domain
but no MBD domain. A protein complex contain-
ing MBD2b and MBD3L results in the demethyla-
tion of the paternal genome immediately after
fertilization. A transcriptional repressor domain is
present at the N-terminus of MBD3L and func-
tional assays illustrate its role as a transcriptional
repressor.
Knockout experiments have shown that methyla-
tion is essential for correct cell functioning, however
there is a price to pay for regulation by methylation
since methylation is toxic. The deamination of cyto-
sine gives rise to uracil but the deamination of m
5C
results in thymine i.e. a G/T mismatch. However
MBD4 has a repair domain similar to a DNA gly-
cosylase, which is able to remove the mismatched
base.
Ulrike Hardeland (Institute of Medical Radio-
biology) presented the mechanisms coordinating the
repair of G/T mispairs arising through methylcyto-
sine deamination. Human thymine-DNA glycosylase
(TDG) has a 410 amino acid open reading frame
encoding a protein of 46 KDa, which is highly con-
served in evolution. This monofunctional DNA
glycosylase has a number of implicated biological
roles including; base excision repair, transcriptional
regulation of gene expression and DNA methyla-
tion. A mouse with a TDG knockout shows embryo-
nic lethality at day 10.5 post coitum.
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using a yeast 2-hybrid assay and include the small
ubiquitin-like modiﬁers SUMO-1 and SUMO-3 [6].
TDG is modiﬁed by sumoylation at a single lysine
residue (330 of human TDG) and this SUMO-TDG
shows altered substrate processing. G/U is pro-
cessed by SUMO-TDG whereas G/T is not. In
addition to TDG and MBD4 there are several other
DNA glycosylases; uracil DNA glycosylase (UNG)
and single strand selective monofunctional uracil
DNA glycosylase (SMUG1), so why the apparent
biochemical redundancy? This may be down to cell
cycle related ﬂuctuations. TDG is most abundant
during the G1 phase of the cell cycle and is com-
pletely absent during S phase. The regulation of
TDG is not at the transcriptional level but rather at
the protein level, by ubiquitination prior to S phase.
The differential expression of TDG and UNG
during the cell cycle means there is no biochemical
redundancy.
So what of the functions of the DNA methyl
transferases (DNMTs) in mammalian development?
En Li (Massachusetts General Hospital) discussed
the functions of Dnmt1, Dnmt3a, Dnmt3b and Dnmt3L
in the mouse. Dynamic methylation changes are
observed during mouse development and indicate
different roles for the methyltransferases. Dnmt1 is
a housekeeping hemi-methyltransferase and inacti-
vation of Dnmt1 did not affect global methylation
in the cancer cell-line studied. In contrast, Dnmt3a
and b are essential for de novo methylation. The
Dnmt3a
x/x mutant phenotype manifests as runted
mice with abnormalities in the gastrointestinal tract
e.g. functional obstruction in the cecum (proximal
intestine) and bleeding. Dnmt3a is not expressed in
the epithelial tissue of the gut, but in the ganglia
cells and smooth muscle. Dnmt3b
x/x mutants die
at E14.5–E16.5 with anterior neural tube, ventricu-
lar septal, and liver defects as well as haemorrhage
and oedema. Dnmt3a/b therefore have a broad
range of developmental functions, many of which
are unknown. The Massachusetts group intend to
study tissue speciﬁc gene ablation and identify genes/
sequences methylated by Dnmt3a and 3b during
development. In contrast to 3a and 3b, Dnmt3L
has no enzyme activity but does have a PHD motif
in common with them. Despite its name, Dnmt3L
is not a methyltransferase, but it does have a simi-
lar expression pattern to 3a/b. Dnmt3L
x/x males
are sterile with impaired spermatogenesis. Although
the Dnmt3L
x/x females are fertile, embryos from
pregnant Dnmt3L
x/x mothers die at around E10.5
and interestingly, maternally methylated imprinted
genes such as Igf2r and Peg1 are hypomethylated
intheseembryos.Methylationofpaternallyimprinted
genes such as H19 and Igf2 are unaffected, sug-
gesting that Dnmt3L may cooperate with 3a/b to
regulate spermatogenesis and maternal genomic
imprints. Indeed, a recent paper by Bourc’his and
colleagues [2] conﬁrms that Dnmt3L is critical in
the establishment of maternal genomic imprints.
Epigenetic mechanisms in tumorigenesis
Ina Rhee of Bert Vogelstein’s laboratory (The John
Hopkins University) presented their work demon-
strating that DNMT1 and DNMT3b cooperate to
silence genes in human cancer cells. The role of
methyltransferase enzymes has been largely studied
in mouse models in the past, however Rhee and
colleagues have generated knockouts of DNMT1
and DNMT3b in human colorectal cell-lines. The
HCT116 colorectal carcinoma line was used because
it exhibits hypermethylation-associated gene silen-
cing, a diploid karyotype and susceptibility to
targeted homologous integration. LoxP recombina-
tion was used in the targeted deletion of the
DNMT1 and DNMT3b genes. Human cancer cells
lacking DNMT1 retained 80% of genomic methyla-
tion (including that at Alu and LINE repeat
elements) and associated gene silencing. Disrupting
the DNMT3b gene reduced global DNA methyla-
tion by less than 3%. Next, double knockouts
(DKO) of DNMT1 and DNMT3b were generated
in the same cells. Instead of the anticipated decrease
in methylation of approximately 23%, the research-
ers observed a 95% decrease in genomic DNA
methylation and almost complete elimination of
methyltransferase activity. In the DKO cell-lines,
repeat sequences were demethylated (which is indi-
cative of global demethylation), imprinting of the
IGF2 gene was lost and there was a loss of silencing
of the tumour suppressor gene p16
INK4a. The nor-
mally silenced and hypermethylated TIMP-3 gene is
re-expressed in the DKO cells, with associated
promoter demethylation. In one of the eight DKO
lines generated (DKO 8) higher global m
5C was
seen, as well as retention of p16
INK4a silencing and
robust growth. This DKO 8 clone suggests that
enzymes other than DNMT1 and DNMT3b can be
used by tumour cells to maintain methylation of
critical sites in some circumstances. The DKO lines
therefore represent a good resource for ﬁnding new
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ﬁndings have been published in Nature [8].
DNA methylation and development
David Katz (Princeton University) began this session
with his presentation on epigenetic regulation of
mammalian growth. Mouse distal chromosome 7
(chr7) and the syntenic human region at 11p15 have
a large cluster of imprinted genes including those
responsible for Beckwith-Wiedemann Syndrome
(BWS) in man. The parent speciﬁc expression of
autosomal genes is achieved by the imposition of
epigenetic marks (such as DNA methylation) that
are established in the gametes and then maintained
throughout development. It is already clear that
DNA methylation is functionally responsible for
gene silencing in a number of imprinted genes,
including H19 at mouse distal chr7. Paradoxically,
another gene in the same region, Igf2, requires the
presence of DNA methylation for its expression.
The presence of a chromatin boundary within the
imprinting control region (ICR), upstream of H19
and downstream of Igf2, is thought to block access
of enhancers to Igf2 on the unmethylated maternal
chromosome, keeping it silent. On the paternal
chromosome, methylation blocks the formation of
the boundary and therefore the Igf2 enhancers
enable its expression. The boundary requires the
binding of a zinc-ﬁnger protein, CCCTC binding
factor (CTCF). CTCF binds multiple times in the
H19 region and plays a role in the maintenance
of the maternal allele in an unmethylated state. In
a CTCF mutant, enhancer binding is no longer
blocked, therefore allowing expression of Igf2. The
presence of CTCF in both germ-lines at the time of
imprinting establishment indicates that CTCF is not
responsible for establishing the maternal allele in an
unmethylated state. The H19 ICR is a maternal-
speciﬁc origin of replication (ORC) showing 90%
maternal and only 10% paternal ORC activity. These
ﬁndings are consistent with the model of ORC estab-
lishment of an unmethylated state proposed by
Antequera and Bird [1].
The chair of this session, Wolf Reik (Babraham
Institute) presented his group’s work in elucidating
the function and mechanisms of imprinting and epi-
genetic reprogramming. 50 imprinted genes have
been identiﬁed in mammalian genomes to date and
these genes have a major effect on foetal growth,
placental development and postnatal behaviour.
The genetic conﬂict hypothesis proposes that pater-
nally expressed genes enhance foetal growth having
been selected to recruit resources from the mother
for the foetus, whilst maternal genes suppress foetal
growth by inhibiting resource allocation to the
foetus. The growth factor Igf2 is an important regu-
lator of foetal growth and is highly expressed both
in the placenta and foetus. The expression of this
growth factor determines the size and efﬁciency of
the placenta for nutrient transfer. In BWS, patients
have a very large foetus, due to errors in this region
of 11p15. In order to address the role of Igf2 in
placental function, an Igf2 placental speciﬁc trans-
cript (expressed in the labyrinth trophoblast of
placenta) was studied. A knockout mouse was gene-
rated in which the placental speciﬁc promoter (P0)
was removed, whilst keeping the foetal promoter
intact. The result of this knockout was a placental,
and late foetal, growth restriction, approximately
30% smaller than the wild type. Placental transport
assays in which radioactive food is ingested by the
mother prior to samples being taken from the
foetus, showed that in the mutant P0 mice passive
diffusion is down regulated, whilst active transport
is upregulated, presumably because the smaller
placenta is working harder to provide for the
foetus. The coordination within the same gene is
remarkable, as illustrated by the two alternative
transcripts of Igf2; controlling the supply of nutri-
ents in the placenta, and controlling the demand for
nutrients in the foetus.
DNA methylation/epigenetics
Rudolf Jaenisch (Whitehead Institute for Biomedical
Research) discussed epigenetic reprogramming in the
context of mammalian cloning. His group is inter-
ested in using nuclear cloning of vertebrates as a
tool for deﬁning the epigenetic state. The major
problem encountered in nuclear cloning is genomic
reprogramming, which renders the technique inefﬁ-
cient; most embryos die before birth with severe
abnormalities. Cloned mouse pups display ‘large
offspring syndrome’ which manifests as a huge
placenta and foetus, 4 to 7 times larger than the
wild type. Six known imprinted genes were tested in
these mice and none were expressed correctly, indi-
cating that abnormal imprinting is the cause of
large offspring syndrome. Gene expression proﬁling
using an Affymetrix chip was used to highlight
those genes with reduced or elevated expression
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genome was observed to be deregulated. Higher
survival rates are observed when using embryonic
stem (ES) cells as the nuclear donors by comparison
to somatic cell donors. Somatic stem cells have
similarities with ES cells and therefore those sur-
viving clones thought to have been generated from
somatic cells, may actually have been cloned from
rare stem cells in the cell population.
Gene silencing and development
Ian Wilmut (Roslin Institute) added to the discus-
sion about cloning indicating that the study of
cloned animals, through nuclear transplantation, is
revealing much about epigenetic effects. He began by
saying that while sheep, cattle, mice, goats, pigs and
a cat had all been cloned from somatic cells, the
same teams of researchers, with the same techno-
logy had been unable to clone rabbits, rhesus
monkeys, rats and dogs. Consistent with Rudolf
Jaenisch’s observations, the cloning was seen as
repeatable, but very inefﬁcient, and the problems
observed included increased weight, respiratory dif-
ﬁculty, cardiopulmonary effects, miscarriage, dis-
orders of the immune system and reduced longevity
[7]. The ﬁrst gene-targeted animal at the Roslin
Institute was put down after suffering from respira-
tory problems; the autopsy showed abnormalities in
both lung and kidney tissues. Importantly, the
abnormalities are not always seen in disorders
arising through natural reproduction and since the
phenotypes are not inherited, they must be the
result of epigenetic effects [10]. Work is now under-
way to determine how the nucleus is epigenetically
reprogrammed.
Conclusion
We are entering a new era of functional genomics,
using the reference DNA sequences for a growing
number of vertebrate and invertebrate genomes to
assist in the study of gene function. It is clear from
this meeting that gene function cannot simply be
deﬁned from knowledge of the genomic sequence
but is complicated by the epigenome. The ﬁeld of
epigenetics is a growing one and is full of promise,
both in giving a better understanding of genome
function and in using this understanding to improve
healthcare.
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